reports
- Research Department
IBERIAN DAILY 09 APRIL (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: ALMIRALL, ENAGÁS, MERLIN PROPERTIES, TALGO, TELEFÓNICA. Transitional session Awaiting the release of US inflation data, the ECB meeting and the start of the results season, European stock markets ended with slight gains, lacking a clear driver and with cyclicals favoured, along with widening in sovereign debt. In the STOXX 600, the best-performing sectors were Basic Materials and Autos, whereas Household Goods and Media ended with the biggest drops. On the macro side, in Spain Fun...
- Research Department
INFORME DIARIO 09 ABRIL (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ALMIRALL, ENAGÁS, MERLIN PROPERTIES, TALGO, TELEFÓNICA. Sesión de transición A la espera de la publicación de la inflación estadounidense, la reunión del BCE y el arranque de la temporada de resultados, las bolsas europeas terminaron con ligeras subidas sin un catalizador claro con un claro sesgo a favor de los cíclicos y acompañados de repuntes de rentabilidad en la deuda soberana. En el STOXX 600 los mejores sectores del día fueron R. Básicos y A...
- Research Department
IBERIAN DAILY 14 MARCH (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: ALMIRALL, FERROVIAL, MAPFRE. The IBEX takes flight European stock markets ignored the surprise rise in US inflation and increased their gains, still convinced that rates will begin to fall starting in June. The IBEX rose more than +1.6%, approaching 10,600 points, driven by the rally by Inditex (+7.7%). In the STOXX 600, most sectors closed with gains, led by Retail and Basic Materials, with the biggest losses in Autos and Technology. On the macro side, in the euro zone January’s ...
- Research Department
INFORME DIARIO 14 MARZO (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ALMIRALL, FERROVIAL, MAPFRE. EUROPA: AB INBEV, VINCI. El Ibex vuela Las bolsas europeas obviaron la sorpresa al alza en la inflación de Estados Unidos y aceleraron las ganancias una jornada más mientras permanece el convencimiento de que los tipos bajarán a partir de junio. El Ibex subió más de un 1,6% acercándose a los 10.600 puntos impulsado por el repunte de Inditex (+7,7%). Así, en el STOXX 600, la mayoría de los sectores cerraron con ganancias,...
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to L...
BARCELONA, Spain & WATERTOWN, Mass.--(BUSINESS WIRE)-- Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013. Under the agreement, Almirall obtains global rights to develop and commercialize ZKN-013, including for the use in orphan dermatological diseases. ZKN-013 is a potentially promising oral, nonsense mutation readthrough drug, which enables the host cells to produce functional proteins which counteract the root cause of these rare dermatological and potentially other di...
- Christophe Chaput
- Christophe Chaput
- Juan Ros-Padilla
Almirall SA : Q4 EBITDA in line. NP again below on impairments. FY 202...
>Operating performance with sales momentum and margin deterioration - Sales reached € 218m (-5% y-o-y vs +4% in Q3 and +8% in Q2), somewhat above our estimates but below the consensus. As regards its recent product launches: Ilumetri keeps on with its normalisation (+22% in Q4 +36% in Q3 and +39% in Q2) and Seysara maintains the deterioration observed over the last quarters (-19% vs -25% in Q3 and -26% in Q2 2023). The GM stood at 66% in Q4 2023 (flat y-o-y), in line ...
- Luis Arredondo
- Luis Arredondo
ALMIRALL: RDOS. 4T’23 Y CAMBIO DE P.O. AL ALZA (ANÁLISIS BANCO SABADEL...
Rdos. 4T'23 vs 4T'22: Ventas: 219,9 M euros (-4,1% vs +0,3% BS(e) y -0,4% consenso); EBITDA: 35,8 M euros (-31,0% vs -25,6% BS(e) y -28,7% consenso); EBIT: 5,4 M euros (-75,0% vs -66,2% BS(e) y -74,1% consenso); BDI: -52,1 M euros (-6,6 M euros en 2022 vs -0,4 M euros BS(e) y 4,7 M euros consenso); Rdos. 2023 vs 2022: Ventas: 894,5 M euros (+3,6% vs +4,8% BS(e) y +4,6% consenso); EBITDA: 174,1 M euros (-12,2% vs -10,8% BS(e) y -11,6% consenso); EBIT: 49,8 M euros (-35,9% vs -33,5% BS(e) y -35,6%...
- Research Department
INFORME DIARIO 19 FEBRERO + RDOS. ESPAÑA Y EUROPA 4T’23. PREVIEWS (ANÁ...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ALMIRALL, GRIFOLS. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los previews de Rdos. 4T’23 que se publicarán en España y Europa en los próximos días. Semana de descanso para el Ibex Las bolsas se asustaron con los datos de inflación estadounidense pero la mayoría de índices europeos lograron terminar con avances a excepción del Ibex, que cerró con ligeras pérdidas alejá...
- Research Department
IBERIAN DAILY 19 FEBRUARY + 4Q’23 RESULTS. PREVIEWS (ANÁLISIS BANCO SA...
NEWS SUMMARY: ALMIRALL, GRIFOLS. At the end of today’s report, and during the entire results season, we will include a presentation with previews for the 4Q’23 results to be released over the coming days in Spain. The Ibex paused for a break last week The US inflation data led to stock market fears but most European indices managed to end in positive territory with the exception of the Ibex that closed with slight drops, below the 10,000-point level. Thus, in the STOXX 600, all the sectors exc...
Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk ...
BARCELONA, Spain--(BUSINESS WIRE)-- Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, announced today that it has entered into an exclusive license agreement with Novo Nordisk for rights to the IL-21 blocking monoclonal antibody NN-8828. Under the agreement, Almirall obtains global rights to develop and commercialize this monoclonal antibody in certain fields, including immune inflammatory dermatological diseases. This press release features multimedia. View the full release here: Almirall R&D (Photo: Business Wire) Almirall will accelerate the develo...
Almirall continues its progress to leadership in Medical Dermatology d...
BARCELONA--(BUSINESS WIRE)-- a global biopharmaceutical company based in Barcelona, today announced its full-year 2023 financial results. This press release features multimedia. View the full release here: Almirall HQ in Barcelona (Photo: Business Wire) Financial highlights (€ rounded million) 2023 2022 Variation Total Revenue 898.8 878.5 2.3% Net Sales 894.5 863.2 3.6% Other Income 4.3 15.3 (71.9%) Gross Profit 581.4 572.9 1.5% % of sales 65% ...
- Anthony Dick
- Michael Foundoukidis
- Anthony Dick
- Michael Foundoukidis
- Juan Ros-Padilla
Almirall SA : Q4 earnings preview. We expect the soft momentum to rema...
>Sales to decline by 8% y-o-y due to a hard comp - The company is due to publish its Q4 2023 results on 19 February before the market opens. We expect total sales to decline 8% y-o-y to € 212m (vs +4% in Q3 +8% in Q2 and +2% in Q1). The figure is impacted by a strong comparison basis in Q4 2022, and the exit from the perimeter of Motilex which was perpetually licensed to Teofarma at the end of Q4 2022. At the EBITDA level, we expect a decline of -33% to € 35m, explain...
Almirall Initiates First Phase I Clinical Study of ALM223, an Interleu...
BARCELONA, Spain--(BUSINESS WIRE)-- Almirall S.A. (BME: ALM), a global pharmaceutical company focused on medical dermatology, today announced the initiation of the phase I study evaluating the safety, pharmacokinetics, immunogenicity, and pharmacodynamics of ALM223, an interleukin 2 mutant fusion protein (IL-2 mu-Fc) for the potential treatment of a broad spectrum of immunological diseases. This press release features multimedia. View the full release here: Almirall HQ in Barcelona (Photo: Business Wire) ALM223 is a modified version of the protein IL-2 designed to selectively activate Regulat...
Almirall and etherna Enter Into a Multi-Target Alliance to Develop mRN...
BARCELONA, Spain & NIEL, Belgium--(BUSINESS WIRE)-- Almirall, S.A. (ALM), a global pharmaceutical company focused on medical dermatology, and etherna, an mRNA/LNP technology platform company, announced today a multi-target alliance to discover and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The alliance combines and leverages etherna’s innovative proprietary mRNA capabilities and LNP formulations with Almirall’s leading expertise in medical dermatology to accelerate discovery of novel treatment options. Delivery of LNP-formulated mRNA for tr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.